S

SAB Biotherapeutics Inc
NASDAQ:SABS

Watchlist Manager
SAB Biotherapeutics Inc
NASDAQ:SABS
Watchlist
Price: 3.74 USD -0.8% Market Closed
Market Cap: 178.1m USD

SAB Biotherapeutics Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

SAB Biotherapeutics Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
S
SAB Biotherapeutics Inc
NASDAQ:SABS
Free Cash Flow
-$34.6m
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$19.7B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$9.7B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.9B
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
20%
No Stocks Found

SAB Biotherapeutics Inc
Glance View

Market Cap
177.6m USD
Industry
Biotechnology

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Sioux Falls, South Dakota and currently employs 139 full-time employees. The company went IPO on 2021-01-12. The firm offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The firm is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.

SABS Intrinsic Value
0.13 USD
Overvaluation 97%
Intrinsic Value
Price
S

See Also

What is SAB Biotherapeutics Inc's Free Cash Flow?
Free Cash Flow
-34.6m USD

Based on the financial report for Dec 31, 2024, SAB Biotherapeutics Inc's Free Cash Flow amounts to -34.6m USD.

What is SAB Biotherapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-57%

Over the last year, the Free Cash Flow growth was -37%. The average annual Free Cash Flow growth rates for SAB Biotherapeutics Inc have been -57% over the past three years .

Back to Top